Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Photo of Scott G. Franzblau

Scott G. Franzblau

Director, Institute for Tuberculosis Research
Albert Schatz Professor, College of Pharmacy - Pharmaceutical Sciences

About Heading link

Research Interests:
1) New drug discovery for tuberculosis, non-tuberculous mycobacteria, Lyme Disease and ESKAPE pathogens
2) Antimicrobial assay development
3) Isolation of novel minor bioactive secondary metabolites

Teaching and Supervision Heading link

PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
PSCI Ph.D. Thesis Research (PSCI 599), 8/23/2021 – 12/3/2021
PHAR 506 (PHAR 506), 2/24/2021 – 2/24/2021
Undergrad Res Exp MedChem&Pcog (PMMP 300), 1/14/2019 – 5/3/2019
Spec Project Med Chem &Pcog (PMMP 390), 1/9/2017 – 4/28/2017
Fund of Drug Action III (PHAR 333), 8/22/2016 – 12/2/2016
Fund of Drug Action III (PHAR 333), 8/22/2016 – 12/2/2016
Lab Tech in Pcog I (PMPG 590), 1/11/2016 – 4/29/2016

Selected Grants

To identify natural product molecules with potential activity against tuberculosis, National Institutes of Health (National Cancer Institute)., 1/6/2023 - 1/5/2025, No Obligated Amount Set; No Anticipated Amount Set

Design, Syntheses and Studies of Novel Antituberculosis Agents, University of Notre Dame., 9/1/2021 - 8/31/2023, Obligated Amount: $185798; Anticipated Amount: $185798

Provide heat inactivated cell suspensions of four mycobacterial strains to EpicGenetics, EpicGenetics., 8/1/2021 - 1/31/2022, Obligated Amount: $3980; Anticipated Amount: $3980

In Vitro testing of candidate anti-tubercular compounds (Master under 109178), Global Alliance for TB Drug Development., 4/1/2021 - 4/30/2023, Obligated Amount: $747690; Anticipated Amount: $747690

★ Modulation of Protein production and Degradation as an integrated approach to rapid sterilization of Drug sensitive and resistant Mtb, Global Alliance for TB Drug Development., 4/1/2019 - 3/31/2023, Obligated Amount: $7080805; Anticipated Amount: $7080805

A new paradigm for the creation and mining of microbial libraries for drug discovery, National Institutes of Health (National Institute of General Medical Sciences)., 8/10/2018 - 7/31/2023, Obligated Amount: $2069671; Anticipated Amount: $2069671

Enhancing basic and translational TB research in northern Vietnam, National Institutes of Health., 7/1/2017 - 6/30/2022, Obligated Amount: $52396; No Anticipated Amount Set

A Novel Antibiotic Strategy Exploiting Metabolite Self-Toxicity, Chicago Biomedical Consortium., 3/1/2017 - 2/28/2019, Obligated Amount: $100000; Anticipated Amount: $100000

★ In Vitro Testing of Candidate Anti-Tubercular Compounds (MASTER under 109178), Global Alliance for TB Drug Development., 10/1/2005 - 3/31/2021, Obligated Amount: $10312702; Anticipated Amount: $10312702

Selected Publications

Lee, SY, Shetye, GS, Son, SR, Lee, H, Klein, LL, Yoshihara, JK, Ma, R, Franzblau, SG, Cho, S, Jang, DS. (2023). Anti-Microbial Activity of Aliphatic Alcohols from Chinese Black Cardamom (Amomum tsao-ko) against Mycobacterium tuberculosis H37Rv. Plants, 12, (1). doi:10.3390/plants12010034.

Ristroph, KD, McManus, SA, Shetye, G, Cho, SH, Lee, D, Szekely, Z, Sinko, PJ, Franzblau, SG, Prud’homme, RK. (2022). Targeted Antitubercular Peptide Nanocarriers Prepared by Flash NanoPrecipitation with Hydrophobic Ion Pairing. Advanced Materials Technologies, 7, (11). doi:10.1002/admt.202101748.

Liu, R, Marshall, K, Ma, R, Lien Thi Pham, K, Shetye, G, Liu, Z, Cho, S, Jeong, H, Franzblau, SG, Moraski, GC, Miller, MJ. (2022). Syntheses and studies of deuterated Imdiazo[1,2-a]pyridine-3-carboxamides with potent anti-tuberculosis activity and improved metabolic properties. Bioorganic Chemistry, 128. doi:10.1016/j.bioorg.2022.106074.

Zhou, B, Shetye, G, Wolf, NM, Chen, SN, Qader, M, Ray, GJ, Lankin, DC, Cho, S, Cheng, J, Suh, JW, Franzblau, SG, McAlpine, JB, Pauli, GF. (2022). New Rufomycins from Streptomyces atratus MJM3502 Expand Anti- Mycobacterium tuberculosis Structure-Activity Relationships. Organic Letters, 24, (40), 7265-7270. doi:10.1021/acs.orglett.2c02493.

Ang, CW, Lee, BM, Jackson, CJ, Wang, Y, Franzblau, SG, Francisco, AF, Kelly, JM, Bernhardt, PV, Tan, L, West, NP, Sykes, ML, Hinton, AO, Bolisetti, R, Avery, VM, Cooper, MA, Blaskovich, MAT. (2022). Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection. Journal of Medicinal Chemistry, 65, (19), 13125-13142. doi:10.1021/acs.jmedchem.2c00972.

Luo, W, Huang, Z, Xu, D, Yang, M, Zhu, Y, Shen, L, Chen, S, Tao, X, Bin, W, Hu, Y, Franzblau, SG, Jiang, N, Wei, Y, Wei, X, Ding, CZ. (2022). Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent. Bioorganic and Medicinal Chemistry Letters, 72. doi:10.1016/j.bmcl.2022.128871.

Huang, Z, Luo, W, Xu, D, Guo, F, Yang, M, Zhu, Y, Shen, L, Chen, S, Tang, D, Li, L, Li, Y, Wang, B, Franzblau, SG, Ding, CZ. (2022). Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent. Bioorganic and Medicinal Chemistry Letters, 71. doi:10.1016/j.bmcl.2022.128824.

Brullo, C, Caviglia, D, Spallarossa, A, Alfei, S, Franzblau, SG, Tasso, B, Schito, AM. (2022). Microbiological Screening of 5-Functionalized Pyrazoles for the Future Development of Optimized Pyrazole-Based Delivery Systems. Pharmaceutics, 14, (9). doi:10.3390/pharmaceutics14091770.

Sutherland, HS, Choi, PJ, Lu, GL, Giddens, AC, Tong, AST, Franzblau, SG, Cooper, CB, Palmer, BD, Denny, WA. (2022). Synthesis and Structure–Activity Relationships for the Anti-Mycobacterial Activity of 3-Phenyl-N-(Pyridin-2-ylmethyl)Pyrazolo[1,5-a]Pyrimidin-7-Amines. Pharmaceuticals, 15, (9). doi:10.3390/ph15091125.


B.S, Rutgers University, United States, 1976
MS, University of Arizona, United States, 1978
PhD, University of Arizona, United States, 1982

Postgraduate Training:
Postgraduate, Kurume University, Japan, 1984